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Background: Isodicentric 15 syndrome (IDIC-15) is due to partial duplications of chromosome 15 that may includes
the q11–13 region that includes genes encoding the α5 (GABRA5) and β3 - γ3 (GABRB3) receptor subunits. The
disease causes intellectual and physical developmental delay, seizures, intellectual disability and behavioral disorders
that may be related to abnormal GABA receptor function and morphology. Seizures are often severe and may be
refractory to treatment. There are however no specific guidelines for the treatment of the seizures and it is
unknown whether drugs that affect the GABAergic system have a different effect in IDIC-15 seizures.
Case presentation: We report the case of an adult individual with IDIC-15 whose complex-partial seizures
worsened dramatically after the introduction of pregabalin, with increased seizure frequency, frequent
generalization, and appearance of new seizure pattern. Her cognitive function and verbal skills also worsened
during treatment with pregabalin. Her seizures and cognitive skills quickly improved after pregabalin was
discontinued and treatment with lacosamide started.
Conclusion: As her genetic testing confirmed that her region of duplication included GABA receptor encoding
genes, it is plausible that the worsening of seizures were due to induction of an abnormal GABAergic response to
pregabalin.This case may help define proper therapeutic strategies for the treatment of IDIC-15 associated seizures.
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Different rearrangements may occur in the chromosome
region 15q11–13, which is quite unstable because of
repeated DNA elements. The rearrangements include
deletions associated either with Angelman syndrome or
with Prader-Willi syndrome, translocations, inversions and
supernumerary marker chromosomes formed by the
inverted duplication of proximal chromosome 15. Interstitial
duplications, triplications and balanced reciprocal transloca-
tions are quite rare while the inversion duplication 15 or
idic15 is the most common of the extra structurally* Correspondence: alessandro.dirocco@med.nyu.edu
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reproduction in any medium, provided the orabnormal chromosomes. The duplication extension may be
variable and may contain or not the Prader-Willi/
Angelmann syndrome critical region q11–13.
Isodicentric 15 syndrome (IDIC-15) is caused by
partial duplications of chromosome 15, usually including
the q11–13 region that is rearranged as a supernumerary
pseudodicentric chromosome or more rarely as an inter-
stitial duplication [1,2]. The typical phenotype includes
physical and intellectual developmental delay with intel-
lectual disability, seizures, behavioral abnormalities often
of the autistic spectrum, and minor facial dysmorphism
[3,4]. The significant variability of the severity of the
syndrome can be attributed to the length of the chromo-
somal duplication, gene dosing effect and epigenetic
mechanisms [2,5,6]. There are very few long-termal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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known whether, age-related neurological problems mani-
fest in any specific manner in people with IDIC-15, as it
occurs in other chromosomal diseases [3].
Seizures are very common in children and adults with
IDIC-15. A wide spectrum of seizure disorders have
been reported, including absence seizures, myoclonic
epilepsy, complex partial seizures, generalized tonic-
clonic seizures, and Lennox-Gastaut like-syndrome. Not
uncommonly, affected individuals have complex epilep-
tic patterns that are refractory to treatment [7-10].
Although the mechanism has not been firmly identified,
seizures may be due to abnormal γ-aminobutyric acid
(GABA)-A receptor configuration, as the affected region
on chromosome 15q includes genes encoding the α5
(GABRA5) and β3 - γ3 (GABRB3) receptor subunits
[11-13]. There are no established guidelines for the
treatment of epilepsy in IDIC-15, nor is it known
whether the GABA receptor abnormalities affect the
response to anti-epileptic drugs, or if the seizure dis-
order evolves with age.
We report severe paradoxical worsening of epilepsy in
an adult woman with IDIC-15 with complex partial
seizures and secondary generalization who had been
treated with Pregabalin and a dramatic improvement
after the drug was discontinued.Figure 1 (A) Array-CGH graphical overview of chromosome 15 duplic
A_16_P02992133 (20,102,541 bp, first deleted) and A_16_P02998642 (28,53
Genes GABRB3, GABRG3, and GABRA5 are circled.Case presentation
The subject of this report is a 53-year-old woman with
IDIC-15 with psychomotor slowing and moderately severe
intellectual disability. Cytogenetic analysis evidenced a large
supernumerary IDIC (15) in all the cells analyzed. To better
characterize the abnormal chromosome, an array-CGH ana-
lysis was performed using the Agilent Human Genome CGH
Microarray Kit G3 180 K platform (Agilent Technologies,
Santa Clara, CA, USA), according to manufacturer’s protocol.
Results showed a duplication encompassing 8.433 Mb be-
tween oligomers A_16_P02992133 (20,102,541 bp, first dupli-
cated) and A_16_P02998642 (28,535,051 bp, last duplicated)
(Figure 1A, B). The duplicated region harbors about 21 genes
according to the UCSC Genome Browser (http://genome.
ucsc.edu/; GRCh37/hg19, February 2009). Among these,
in our opinion, GABRB3 (gamma-aminobutyric acid A
receptor, beta 3, MIM 137192), GABRA5 (Homo sapi-
ens gamma-aminobutyric acid A receptor, alpha MIM
137142) and GABRG3 (gamma-aminobutyric acid A re-
ceptor, gamma 3 MIM 600233) genes could have a role
in causing at least some phenotypic features of our
proposita.
Her seizure disorder first appeared at age 24 when she
developed complex partial seizures with staring and
blanking-out episodes accompanied by stereotypical
head turning or raising of the arms, without loss ofation. The 15q11.1q13.1 duplicated region extends between probes
5,051 bp, last deleted). (B) Gene content of the duplicated region.
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At age 24 she also had an isolated generalized tonic-
clonic seizure and was started on carbamazepine. Over
the years, the complex partial seizures episodes became
more frequent and when she was 34 years of age,
Lamotrigine was added. As the frequency of the complex
partial seizures increased, both drugs were kept at a
dosing level to sustain serum medication levels at the
higher limits of the norm. When she was 46 years old,
oxcarbazepine was initiated and carbamazepine stopped.
At age 50 she had a fall and sustained severe head
trauma that caused a large left parietal subdural
hematoma and a small frontal contusion. After emergent
surgical evacuation of the hematoma her seizures be-
came more frequent with complex-partial episodes that
occurred almost daily and often up to three times in a
day that were of longer duration and accompanied by
more prominent stereotypical hand and arm move-
ments. An EEG could not be obtained as she did not tol-
erate the procedure and could not cooperate with the
execution of the test. The daily doses of oxcarbazepine
and lamotrigine were increased respectively to 1200 mg
daily in two divided doses and 700 mg in three divided
doses, with blood levels for both drugs sustained at the
upper limits of the normal range. The change in dosing
was only mildly effective, with seizure occurring four or
five times per week, and she developed clear signs of
drug toxicity with ataxia and imbalance and occasional
nausea and vomiting. A year after the trauma, Pregabalin
was added with doses that were slowly increased to
150 mg/day in three divided doses. Soon after she expe-
rienced a dramatic worsening of her seizures. Her com-
plex partial crisis became more frequent and severe,
with numerous episodes of staring accompanied by more
prominent automatisms with raising of the arms above
the head, forward bending of the trunk, head turning
usually to the right, without falls. The episodes lasted up
to 15–20 seconds and were followed by several minutes
of obtundation and aphasic garbled speech. A new seiz-
ure pattern also developed, with atonic seizures charac-
terized by sudden arrest and falls with altered level of
consciousness and atonia. The dose of Pregabalin was
then increased to the maximum tolerated dose of
300 mg daily in three divided doses, and her seizures be-
came even more severe. Within days from the increase
in dose she had an episode of four episodes of general-
ized tonic-clonic seizures followed in the following
weeks by three more tonic-clonic seizures that lasted up
to five minutes and were followed by prolonged post-
ictal confusion, while continuing to experience frequent
complex-partial seizures and atonic seizures. Most of the
seizures were witnessed by one of the authors (PDR).
She had also become cognitively more impaired, losing
verbal capacity and often appearing obtunded and hadbecome incontinent of urine and feces while remaining
ataxic. Suspecting that the worsening of seizure fre-
quency and the appearance of new seizure patterns were
related to the addition of Pregabalin, the drug was ta-
pered and eventually discontinued while Lacosamide
was introduced and increased to a dose of 100 mg twice
daily. Within two weeks of the drug change she experi-
enced a dramatic improvement that has lasted now for
over twelve months, with only one or two episodes of
complex partial seizures per month with few and limited
stereotypies, and no additional atonic crisis or general-
ized seizures. Her ataxia has also improved as the doses
of Oxcarbazepine and Lamotrigine and have been de-
creased to 900 mg daily and 600 mg daily and she has
resumed her routine life at home and in the day pro-
gram that she attends, regaining her prior level of motor
and intellectual performance and continence.
Discussion
The IDIC-15 subject that we report had a dramatic
worsening of her seizures when Pregabalin was added as
third drug to ongoing treatment with lamotrigine and
oxacarbazepine and almost complete seizure control
when Pregabalin was stopped and lacosamide added.
Pregabalin is a gamma-aminobutyric acid (GABA)
analog, structurally derived from GABA by the addition
of an aliphatic side chain at the 3-position (S-(+)-3-iso-
butyl-GABA). Its anti-epileptic effect is mediated by the
high-affinity binding to the α2δ subunit of the voltage-
dependent calcium channel [14]. Although it is structur-
ally related to GABA, pregabalin at therapeutic doses
does not bind to GABA-A or GABA-B receptors, nor
affects GABA uptake or degradation [15,16]. There is how-
ever evidence that in human motor cortex pregabalin pro-
duces a physiological effect similar to that of GABAergic
drugs [17] and the drug affects the GABA transporter
GAT-1, increasing neuronal GABA uptake [18].
There is no obvious explanation for the seizure wors-
ening induced by pregabalin. In IDIC-15 both the intel-
lectual disability and the seizure disorder are likely
related to the abnormal GABA receptor morphology
and function. The IDIC 15 chromosome in the subject
we report, includes 8 Mb spanning 15q11-13.1 and
results in 4 copies of the 21 genes found in this genomic
interval, including genes encoding GABRB3, GABRA5,
and GABRG3, and it is likely that the abnormal receptor
configuration and distribution may modify the affinity of
pregabalin for GABA receptors and its pharmacological
effect. Interestingly, microdeletions in the 15q11.2 in the
proximal BP1 – BP3 and BP2 – BP3 regions, have also
been associated with a varied phenotype that include
developmental and language delay, intellectual deficit,
behavioral problems, autism, and seizures [19]. The
mechanism leading to the neurological dysfunction is
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NIPA1 and CYFIP1genes that are important in neuro-
logical development [19]. Other microdeletions in the
15q13.3 have been associated with idiopathic generalized
epilepsy and other neuropsychiatric disorders including
autism, schizophrenia, and autism [20]. Among the most
common microdeletions are those affecting CHRNA7 in
the BP4-BP5 region, the gene encoding the alpha 7 sub-
unit of the nicotinic receptor [21], which can modulate
GABA receptors’ function [22]. While it is possible that
seizure activity can be related to abnormal cholinergic
modulatory activity, in our case the duplication does not
encompass the more distal BP4 – BP5 regions of the
CHRNA 7 gene.
Increased of seizure activity and modification of seizures
patterns have been reported with other drugs, including
the GABAergic drugs vigabatrin [23] and tiagabine [24]
and as well as drugs that are not GABAergic such as
levetiracetam [25]. Gabapentin, a drug pharmacologically
related to pregabalin, has been reported to induce life-
threatening myoclonic status in a patient with benign
adult familial myoclonic epilepsy [26]. While there may be
other reasons that could explain the severe exacerbation
of the seizure disorder after the introduction of pregabalin,
the temporal coincidence and the worsening of the seizure
disorder with increased dose of the drug suggest a direct
effect of the drug. It is unlikely that the dramatic increase
in seizure frequency and the appearance of different seiz-
ure patterns can be explained by a late effect of the
trauma. While the subject’s stereotypical seizures had in-
creased in frequency, the dramatic worsening occurred a
year after the trauma, when pregabalin was introduced.
Further, the progressive worsening of her seizures with
increasing dose of pregabalin, the appearance of unusual
seizure patterns, and the rapid improvement after
pregabalin was removed and lacosamide introduced point
to a pharmacological cause. It is however impossible to
determine whether the dramatic improvement that she
then experienced was due to the removal of pregabalin,
the addition of lacosamide, or a combined effect.Conclusion
This case suggests that pregabalin and possibly other
GABA analogs or gabaergic drugs should be used cau-
tiously in individuals with IDIC- as the abnormal GABA
receptor configuration and physiology could alter the
pharmacological response to the drugs. Lacosamide, and
presumably other ionic pump inhibitors may instead be
safer and more effective in subjects with IDIC-15. This
case also indirectly illustrates that people with IDIC-15
can maintain a stable level of neurological and intellec-
tual function well into mature age if seizures are con-
trolled. We believe that as with other rare diseases, evena single case experience may be helpful to clinicians
treating seizures in individual with IDIC-15.
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